# Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

> **NCT05761366** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 400 (estimated)

## Conditions studied

- Malignancy

## Interventions

- **DRUG:** Al18F-PSMA-BCH PET/CT

## Key facts

- **NCT ID:** NCT05761366
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-13
- **Primary completion:** 2025-10-13
- **Final completion:** 2025-10-13
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05761366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05761366, "Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05761366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*